Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A phase 2, randomised, double-blind, placebo-controlled study
- Martin, M.
- Roche, H.
- Pinter, T.
- Crown, J.
- Kennedy, M.J.
- Provencher, L.
- Priou, F.
- Eiermann, W.
- Adrover, E.
- Lang, I.
- Ramos, M.
- Latreille, J.
- Jagiełło-Gruszfeld, A.
- Pienkowski, T.
- Alba, E.
- Snyder, R.
- Almel, S.
- Rolski, J.
- Munoz, M.
- Moroose, R.
- Hurvitz, S.
- Baños, A.
- Adewoye, H.
- Hei, Y.-J.
- Lindsay, M.-A.
- Rupin, M.
- Cabaribere, D.
- Lemmerick, Y.
- Mackey, J.R.
- Show all authors +
ISSN: 1470-2045
Year of publication: 2011
Volume: 12
Issue: 4
Pages: 369-376
Type: Article